Navigation Links
Senesco Technologies to Present at BIO 2008 Business Forum

NEW BRUNSWICK, N.J., June 12 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT) today announced that the Company will be presenting at the Business Forum during BIO 2008, the Biotechnology Industry Organization's Annual International Convention, which is being held at the San Diego Convention Center from June 17-20, 2008. Bruce Galton, Chief Executive Officer of Senesco, will deliver the Company's corporate presentation on Wednesday, June 18th, at 3:30 p.m. local time in Room 2.

The BIO Business Forum is the largest partnering and networking program in the industry. It offers pharmaceutical and biotechnology companies, academic research institutions and investors from around the world the unique opportunity to gather in one place at one time to learn about each other and meet one-on-one to discuss business opportunities of mutual interest.

About Senesco Technologies, Inc.

Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if its technology is applicable in human medicine. Accelerating apoptosis may have applications to the development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as glaucoma, ischemia and arthritis, among others. Senesco takes its name from the scientific term for the aging of plant cells: senescence. The Company has developed technology that regulates the onset of cell death. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress for flowers, fruits and vegetables. In addition to its human health research programs, the Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products. Senesco is headquartered in New Brunswick, N.J.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the successful conversion of the Company's letter of intent into a license agreement; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

SOURCE Senesco Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
2. Senesco Technologies Regains Compliance With Amexs Continued Listing Requirements
3. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
4. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
5. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
6. BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering
7. Spine Surgeons at Pine Creek Medical Center Take the Lead in Utilizing Stem Cell Technologies in Surgical Procedures
8. Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc.
9. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
10. BioStorage Technologies Forms Scientific Advisory Board with Leading Life Science Experts
11. Pelikan Technologies Appoints Denny Ware to Board of Directors
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... Amgen, will join the faculty of the University of North Carolina Kenan-Flagler ... of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s ...
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology:
(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
(Date:3/22/2016)... and SANDY, Utah , March ... operates the highest sample volume laboratory in ... and UNIConnect, leaders in clinical sequencing informatics and molecular ... of a project to establish the informatics infrastructure for ... NSO has been contracted by the Ontario Ministry ...
(Date:3/18/2016)... LONDON , March 18, 2016 ... Established Suppliers of Biometrics, ICT, Manned & Unmanned Vehicles, Physical ... & security companies in the border security market and ... and Europe has led ... your companies improved success. --> defence & ...
Breaking Biology News(10 mins):